Chairs:
Riccardo Dalla-Favera, Columbia University, New York, NY
Sonali M. Smith, University of Chicago, Chicago, IL

Cochairs:
Francesco Bertoni, Institute of Oncology Research, Bellinzona, Switzerland*
Alexey V. Danilov, City of Hope National Medical Center, Duarte, CA
Michael R. Green, The University of Texas MD Anderson Cancer Center, Houston, TX
Ari M. Melnick, Weill Cornell Medical College / Cornell University, New York, NY
Teresa Palomero, Columbia University, New York, NY
Margaret A. Shipp, Dana Farber Cancer Institute, Boston, MA
Christian Steidl, BC Cancer, Vancouver, BC, Canada
Karin Tarte, University of Rennes, Rennes, France

* - ICML Representative

[ R ] – REMOTE PRESENTATION

DO NOT INCLUDE IN ON-DEMAND PROGRAM
THURSDAY, JUNE 23

Registration
12:00 pm-7:00 pm | America Ballroom Foyer

Welcome and Opening Keynote Session
3:00 pm-5:00 pm | America Ballroom North and Center

3:00-3:10 Welcome and Introduction of Keynote Speaker
Riccardo Dalla-Favera, Columbia University, New York, NY

3:10-3:40 Therapeutic vulnerabilities uncovered by B-cell/stromal crosstalk
Karin Tarte, University of Rennes, Rennes, France

3:40-3:50 Q&A / Discussion

3:50-3:55 Introduction of Keynote Speaker
Riccardo Dalla-Favera, Columbia University, New York, NY

3:55-4:25 [ R ] - Integrating bispecific antibodies into lymphoma therapy
Adrian U. Wiestner, National Heart, Lung, and Blood Institute, Bethesda, MD

4:25-4:35 Q&A / Discussion

4:35-5:00 Panel Discussion

Break
5:00 pm-5:30 pm | America Ballroom Foyer
Plenary Session 1: CAR-T
5:30 pm-7:00 pm | America Ballroom North and Center
Session Chair: Sattva S. Neelapu, The University of Texas MD Anderson Cancer Center, Houston, TX

5:30-5:50  Lessons from CD19 CAR T-cell therapy in B-cell non-Hodgkin lymphoma
Sattva S. Neelapu, The University of Texas MD Anderson Cancer Center, Houston, TX

5:50-5:55  Q&A / Discussion

5:55-6:15  Anti-CD19 Chimeric Antigen Receptor T-cells in CLL: A decade in review
Jan Joseph Melenhorst, Cleveland Clinic Lerner Research Institute, Cleveland, OH

6:15-6:20  Q&A / Discussion

6:20-6:40  Challenge accepted: CAR-T cells for T-cell malignancies
Rayne H. Rouce, Baylor College of Medicine, Houston, TX

6:40-6:45  Q&A / Discussion

6:45-7:00  Panel Discussion

Opening Reception
7:00 pm-9:00 pm | America Ballroom South

FRIDAY, JUNE 24

Breakfast
7:00 am-8:00 am | America Ballroom South

Special Session 1: Initial Treatment of DLBCL: Are We in a New Era?
7:30 am-8:30 am | America Ballroom North and Center
Session Chair: Laurie H. Sehn, BC Cancer, Vancouver, BC, Canada

7:30-7:45  Molecular classification of DLBCL: Utility and barriers to implementation
Grzegorz S. Nowakowski, Mayo Clinic College of Medicine and Science, Rochester, MN

7:45-7:50  Q&A / Discussion

7:50-8:05  Is there a new one-size-fits-all standard of care in DLBCL?
Laurie H. Sehn, BC Cancer, Vancouver, BC, Canada

8:05-8:10  Q&A / Discussion

8:10-8:30  Panel Discussion
Break
8:30 am-8:45 am | America Ballroom Foyer

Plenary Session 2: Evolution of Liquid Biopsies for Lymphoma
8:45 am-10:15 am | America Ballroom North and Center
Session Chair: Davide Rossi, Institute of Oncology Research, Bellinzona, Switzerland

8:45-9:05  Understanding the biology of classic Hodgkin lymphoma using circulating tumor DNA
  Davide Rossi, Institute of Oncology Research, Bellinzona, Switzerland

9:05-9:10  Q&A / Discussion

9:10-9:30  Circulating tumor DNA profiling for noninvasive disease detection and MRD monitoring in patients with CNS lymphoma
  Florian Scherer, University Medical Center Freiburg, Freiburg, Germany

9:30-9:35  Q&A / Discussion

  David M. Kurtz, Stanford University Medical Center, Stanford, CA

9:55-10:00  Q&A / Discussion

10:00-10:15  Panel Discussion

Break
10:15 am-10:30 am | America Ballroom Foyer
### Plenary Session 3: Germinal Center Biology
10:30 am-12:00 pm | America Ballroom North and Center  
*Session Chair: Riccardo Dalla-Favera, Columbia University, New York, NY*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30-10:50</td>
<td>[ R ] – T cell help and B cell selection in germinal centers</td>
</tr>
<tr>
<td></td>
<td>Gabriel D. Victora, The Rockefeller University, New York, NY</td>
</tr>
<tr>
<td>10:50-10:55</td>
<td>Q&amp;A / Discussion</td>
</tr>
<tr>
<td>10:55-11:15</td>
<td>Human germinal center responses to vaccination</td>
</tr>
<tr>
<td></td>
<td>Michela Locci, Perelman School of Medicine, University of Pennsylvania,</td>
</tr>
<tr>
<td></td>
<td>Philadelphia, PA</td>
</tr>
<tr>
<td>11:15-11:20</td>
<td>Q&amp;A / Discussion</td>
</tr>
<tr>
<td>11:20-11:40</td>
<td>[ R ] - Lymphoma mutations in the evolution of pathogenic autoantibodies</td>
</tr>
<tr>
<td></td>
<td>Joanne Reed, The Westmead Institute for Medical Research, Westmead, NSW,</td>
</tr>
<tr>
<td></td>
<td>Australia</td>
</tr>
<tr>
<td>11:40-11:45</td>
<td>Q&amp;A / Discussion</td>
</tr>
<tr>
<td>11:45-12:00</td>
<td>Panel Discussion</td>
</tr>
</tbody>
</table>

**Lunch Available**  
12:00 pm-1:30 pm | America Ballroom South

### Plenary Session 4: Epigenetics
1:30 pm-3:00 pm | America Ballroom North and Center  
*Session Chair: Laura Pasqualucci, Columbia University Irving Comprehensive Cancer Center, New York, NY*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30-1:50</td>
<td>BAF complex deregulation in lymphoma</td>
</tr>
<tr>
<td></td>
<td>Michael R. Green, The University of Texas MD Anderson Cancer Center, Houston, TX</td>
</tr>
<tr>
<td>1:50-1:55</td>
<td>Q&amp;A / Discussion</td>
</tr>
<tr>
<td>1:55-2:15</td>
<td>Novel interactions between epigenetic regulators altered in B cell lymphoma</td>
</tr>
<tr>
<td></td>
<td>Laura Pasqualucci, Columbia University Irving Comprehensive Cancer Center, New York, NY</td>
</tr>
<tr>
<td>2:15-2:20</td>
<td>Q&amp;A / Discussion</td>
</tr>
<tr>
<td>2:20-2:40</td>
<td>How to leverage epigenetic therapeutic interventions in FL?</td>
</tr>
<tr>
<td></td>
<td>Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, NY</td>
</tr>
<tr>
<td>2:40-2:45</td>
<td>Q&amp;A / Discussion</td>
</tr>
<tr>
<td>2:45-3:00</td>
<td>Panel Discussion</td>
</tr>
</tbody>
</table>
Break
3:00 pm-3:15 pm | America Ballroom Foyer

Plenary Session 5: Modeling for Pre-clinical
3:15 pm-4:45 pm | America Ballroom North and Center

Session Chair: Giorgio Inghirami, Weill Cornell Medicine, New York, NY

3:15-3:35  Pre-clinical investigation using patient-derived xenograft modeling of aggressive and indolent B-cell lymphomas
Abner Louissaint, Massachusetts General Hospital, Boston, MA

3:35-3:40  Q&A / Discussion

3:40-4:00  Modeling EZH2 mutant follicular lymphomas
Wendy Béguelin, Weill Cornell Medicine, New York, NY

4:00-4:05  Q&A / Discussion

4:05-4:25  Translational research on mantle cell lymphoma: From lab to clinic
Michael Wang, The University of Texas MD Anderson Cancer Center, Houston, TX

4:25-4:30  Q&A / Discussion

4:30-4:45  Panel Discussion

Poster Session / Reception
5:00 pm-7:00 pm | America Ballroom South
SATURDAY, JUNE 25

Breakfast
7:00 am-8:00 am | America Ballroom South

Special Session 2: Mantle Cell Lymphoma
7:30 am-8:30 am | America Ballroom North and Center
Session Chair: Francesco Bertoni, Institute of Oncology Research, Bellinzona, Switzerland

7:30-7:45 Dynamic changes in gene mutational landscape with preservation of core mutations in mantle cell lymphoma
Mariusz A. Wasik, Fox Chase Cancer Center, Philadelphia, PA

7:45-7:50 Q&A / Discussion

7:50-8:05 [ R ] - Targeting SOX11 in mantle cell lymphoma
Samir Parekh, Icahn School of Medicine at Mount Sinai, New York, NY

8:05-8:10 Q&A / Discussion

8:10-8:30 Panel Discussion

Break
8:30 am-8:45 am | America Ballroom Foyer

Plenary Session 6: DLBCL: Genomics Toward Precision Therapy
8:45 am-10:15 am | America Ballroom North and Center
Session Chair: Riccardo Dalla-Favera, Columbia University, New York, NY

8:45-9:05 Leveraging functional and structural genomics for precision medicine
James D. Phelan, National Cancer Institute, Bethesda, MD

9:05-9:10 Q&A / Discussion

9:10-9:30 Understanding lymphoma biology and improving classification through comprehensive sequencing
Ryan D. Morin, Simon Fraser University, Vancouver, BC, Canada

9:30-9:35 Q&A / Discussion

9:35-9:55 Pervasive hypermutation of super-enhancers dysregulates oncogene expression in DLBCL
Riccardo Dalla-Favera, Columbia University, New York, NY

9:55-10:00 Q&A / Discussion

10:00-10:15 Panel Discussion
Break
10:15 am-10:30 am | America Ballroom Foyer

Plenary Session 7: FL and CLL Evolution and Transformation
10:30 am-12:00 pm | America Ballroom North and Center
Session Chair: Catherine J. Wu, Dana Farber Cancer Institute, Boston, MA

10:30-10:50  Human genetic studies: CLL and transformation
            Catherine J. Wu, Dana Farber Cancer Institute, Boston, MA
10:50-10:55  Q&A / Discussion
10:55-11:15  Understanding CLL and Richter's syndrome biology through mouse models of human genetics
            Elisa ten Hacken, Dana Farber Cancer Institute, Boston, MA
11:15-11:20  Q&A / Discussion

11:20-11:40  [ R ] - Follicular lymphoma and transformation
            Jessica Okosun, Queen Mary University of London, London, England
11:40-11:45  Q&A / Discussion

11:45-12:00  Panel Discussion

Lunch Available
12:00 pm-1:30 pm | America Ballroom South

Special Session 3: T-cell Lymphomas
12:30 pm-1:30 pm | America Ballroom North and Center
Session Chair: Teresa Palomero, Columbia University, New York, NY

12:30-12:45  Genomic alterations and mouse models in PTCL
            Teresa Palomero, Columbia University, New York, NY
12:45-12:50  Q&A / Discussion
12:50-1:05   The role of PD1 in t cell lymphomas
            Jaehyuk Choi, Northwestern University, Chicago, IL
1:05-1:10    Q&A / Discussion
1:10-1:30    Panel Discussion
Plenary Session 8: New Technologies
1:45 pm-3:15 pm | America Ballroom North and Center
Session Chair: Kojo S.J. Elenitoba-Johnson, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

1:45-2:05  Lost in ubiquitination, found by mass spectrometry: Novel proteolytic mechanisms implicated in lymphoma transformation
Kojo S.J. Elenitoba-Johnson, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
2:05-2:10  Q&A / Discussion

2:10-2:30  A multi-scale, multiomic atlas of human normal and follicular lymphoma lymph nodes
Andrea Radtke, National Institute of Allergy and Infectious Diseases, Bethesda, MD
2:30-2:35  Q&A / Discussion

2:35-2:55  [ R ] -Elucidation of lymphoma biology by proteogenomics
Thomas Oellerich, Goethe University Hospital, Frankfurt, Germany
2:55-3:00  Q&A / Discussion

3:00-3:15  Panel Discussion

Break
3:15 pm-3:30 pm | America Ballroom Foyer

Plenary Session 9: Immune Evasion in Hodgkin and Non-Hodgkin Lymphomas
3:30 pm-5:00 pm | America Ballroom North and Center
Session Chair: Margaret A. Shipp, Dana Farber Cancer Institute, Boston, MA

3:30-3:50  Genetic bases of immune evasion in lymphoid malignancies
Margaret A. Shipp, Dana Farber Cancer Institute, Boston, MA
3:50-3:55  Q&A / Discussion

3:55-4:15  New imaging approaches to characterize the intact tumor microenvironment
Scott J. Rodig, Brigham and Women's Hospital, Boston, MA
4:15-4:20  Q&A / Discussion

4:20-4:40  The DLBCL immune landscape: Evidence for immune surveillance, evasion, and exclusion
Justin P. Kline, University of Chicago, Chicago, IL
4:40-4:45  Q&A / Discussion
4:45-5:00    Panel Discussion

Break
5:00 pm-5:30 pm | America Ballroom Foyer

Special Session 4: Industry Roundtable
5:30 pm-6:30 pm | America Ballroom North and Center
Session Chair: Anas Younes, AstraZeneca, New York, NY

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker and Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:30-5:40</td>
<td>[ R ] - Adam S. Crystal, C4 Therapeutics, Watertown, MA</td>
</tr>
<tr>
<td>5:40-5:45</td>
<td>Q&amp;A / Discussion</td>
</tr>
<tr>
<td>5:45-5:55</td>
<td>Gwenn Hansen, Nurix Therapeutics, Inc., San Francisco, CA</td>
</tr>
<tr>
<td>5:55-6:00</td>
<td>Q&amp;A / Discussion</td>
</tr>
<tr>
<td>6:00-6:10</td>
<td>Clinical experience with off-the-shelf iPSC derived cell therapies in hematologic malignancies</td>
</tr>
<tr>
<td></td>
<td>Yu-Waye (Wayne) Chu, Fate Therapeutics, San Diego, CA</td>
</tr>
<tr>
<td>6:10-6:15</td>
<td>Q&amp;A / Discussion</td>
</tr>
<tr>
<td>6:15-6:30</td>
<td>Panel Discussion</td>
</tr>
</tbody>
</table>

SUNDAY, JUNE 26

Breakfast
7:00 am-8:00 am | America Ballroom South

Special Session 5: AYA Lymphomas
7:30 am-8:30 am | America Ballroom North and Center
Session Chair: Andrew M. Evens, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker and Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30-7:45</td>
<td>Pathology of AYA lymphomas: Creating a roadmap for translational discovery</td>
</tr>
<tr>
<td></td>
<td>Megan S. Lim, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA</td>
</tr>
<tr>
<td>7:45-7:50</td>
<td>Q&amp;A / Discussion</td>
</tr>
<tr>
<td>7:50-8:05</td>
<td>Unmet clinical research questions in AYA lymphomas</td>
</tr>
<tr>
<td></td>
<td>Jamie E. Flerlage, St. Jude Children’s Research Hospital, Memphis, TN</td>
</tr>
<tr>
<td>8:05-8:10</td>
<td>Q&amp;A / Discussion</td>
</tr>
<tr>
<td>8:10-8:30</td>
<td>Panel Discussion</td>
</tr>
</tbody>
</table>
Break
8:30 am-8:45 am | America Ballroom Foyer

Plenary Session 10: Metabolism and Immunometabolism in Lymphoid Malignancies: A New Target?
8:45 am-10:15 am | America Ballroom North and Center
Session Chair: Ari M. Melnick, Weill Cornell Medical College / Cornell University, New York, NY

8:45-9:05 Metabolic communication between the lymphoma microenvironments
Leandro C. Cerchietti, Weill Cornell Medicine, New York, NY
9:05-9:10 Q&A / Discussion

9:10-9:30 Title to be announced
Nika N. Danial, Dana-Farber Cancer Institute, Boston, MA
9:30-9:35 Q&A / Discussion

9:35-9:55 Multi-omic analysis reveals B-cell stimulus-specific oncogenic pathway responses and targets
Benjamin E. Gewurz, Brigham and Women’s Hospital, Boston, MA
9:55-10:00 Q&A / Discussion

10:00-10:15 Panel Discussion

Break
10:15 am-10:30 am | America Ballroom Foyer

Plenary Session 11: Moving Beyond the Basics in PET: Functional Imaging in Lymphoma
10:30 am-12:00 pm | America Ballroom North and Center
Session Chair: Judith Trotman, University of Sydney, Sydney, Australia

10:30-10:50 Recent and future developments in PET imaging of lymphoma
Heiko Schöder, Memorial Sloan Kettering Cancer Center, New York, NY
10:50-10:55 Q&A / Discussion

10:55-11:15 FDG-PET in FL: Staging, response assessment, and beyond
Stefano Luminari, University of Modena and Reggio Emilia, Modena, Italy
11:15-11:20 Q&A / Discussion

11:20-11:40 PET in diffuse large B cell lymphoma
Judith Trotman, University of Sydney, Sydney, Australia
11:40-11:45 Q&A / Discussion

11:45-12:00 Panel Discussion
Break
12:00 pm-12:15 pm | America Ballroom Foyer

Plenary Session 12: Exploiting NK Cell-therapy in Lymphomas
12:15 pm-1:45 pm | America Ballroom North and Center
Session Chair: Riccardo Dalla-Favera, Columbia University, New York, NY

12:15-12:35 Development of nicotinamide enhanced NK cell therapeutics for lymphoma
Veronika S. Bachanova, University of Minnesota, Minneapolis, MN
12:35-12:40 Q&A / Discussion

12:40-1:00 Driving innate recognition and engineering memory-like NK cells in lymphoma
Melissa M. Berrien-Elliott, Washington University School of Medicine, St. Louis, MO
1:00-1:05 Q&A / Discussion

1:05-1:25 IL-21 expanded, off the shelf, third-party NK cells: Novel therapies for lymphoma
John C. Reneau, The Ohio State University Wexner Medical Center, Columbus, OH
1:25-1:30 Q&A / Discussion

1:30-1:45 Panel Discussion

Closing Comments and Departure
1:45 pm | America Ballroom North and Center

Riccardo Dalla-Favera, Columbia University, New York, NY